{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:50:20Z","timestamp":1780404620367,"version":"3.54.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"16","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":12,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012245","name":"Science and Technology Planning Project of Guangdong Province","doi-asserted-by":"publisher","award":["2023XY007"],"award-info":[{"award-number":["2023XY007"]}],"id":[{"id":"10.13039\/501100012245","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.heliyon.2024.e36311","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T20:28:26Z","timestamp":1723580906000},"page":"e36311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Meta-analysis of effectiveness and safety of proteasome inhibitor-dependent maintenance treatment for multiple myeloma a systematic review"],"prefix":"10.1016","volume":"10","author":[{"given":"Xin-xin","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoli","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujing","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahui","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuefeng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e36311_bib1","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"Kyle","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e36311_bib2","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/bjh.14513","article-title":"Multiple myeloma: routes to diagnosis, clinical characteristics and survival - findings from a UK population-based study","volume":"177","author":"Howell","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.heliyon.2024.e36311_bib3","first-page":"7","article-title":"Cancer statistics","volume":"70","author":"Siegel","year":"2020","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.heliyon.2024.e36311_bib4","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00277-016-2859-8","article-title":"History of autoimmune disease is associated with impaired survival in multiple myeloma and monoclonal gammopathy of undetermined significance: a population-based study","volume":"96","author":"Lindqvist","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.heliyon.2024.e36311_bib5","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.heliyon.2024.e36311_bib6","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1097\/01.jom.0000246229.68697.90","article-title":"Cancer risk among firefighters: a review and meta-analysis of 32 studies","volume":"48","author":"LeMasters","year":"2006","journal-title":"J. Occup. Environ. Med."},{"key":"10.1016\/j.heliyon.2024.e36311_bib7","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1158\/1055-9965.EPI-16-0762-T","article-title":"Young adult and usual adult body mass index and multiple myeloma risk: a pooled analysis in the International Multiple Myeloma Consortium (IMMC)","volume":"26","author":"Birmann","year":"2017","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"10.1016\/j.heliyon.2024.e36311_bib8","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1200\/JCO.2005.10.126","article-title":"Phenotypic heterogeneity in multiple myeloma families","volume":"23","author":"Lynch","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36311_bib9","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/leu.2016.253","article-title":"Hyperhaploidy is a novel high-risk cytogenetic subgroup in multiple myeloma","volume":"31","author":"Sawyer","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2024.e36311_bib10","article-title":"Decursin and doxorubicin are in synergy for the induction of apoptosis via STAT3 and\/or mTOR pathways in human multiple myeloma cells","author":"Jang","year":"2013","journal-title":"Evid Based Complement Alternat Med"},{"key":"10.1016\/j.heliyon.2024.e36311_bib11","doi-asserted-by":"crossref","first-page":"2962","DOI":"10.1182\/blood-2007-10-078022","article-title":"Multiple myeloma","volume":"111","author":"AKyle","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e36311_bib12","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa032290","article-title":"Single versus double autologous stem-cell transplantation for multiple myeloma","volume":"349","author":"Attal","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.heliyon.2024.e36311_bib13","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2002-09-2955","article-title":"Allografting with nonmyeloablative conditioning following cytoreductive autografts for the treatment of patients with multiple myeloma","volume":"102","author":"Maloney","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e36311_bib14","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/leu.2017.211","article-title":"Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65\/GMMG-HD4 trial","volume":"32","author":"Goldschmidt","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2024.e36311_bib15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(18)33003-4","article-title":"Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"93","author":"Dimopoulos","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.heliyon.2024.e36311_bib16","doi-asserted-by":"crossref","first-page":"4030","DOI":"10.1200\/JCO.20.02060","article-title":"Ixazomib as postinduction maintenance for patients with newly diagnosed multiple myeloma not undergoing autologous stem cell transplantation: the phase III TOURMALINE-MM4 trial","volume":"38","author":"Dimopoulos","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36311_bib17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/ejh.13709","article-title":"Carfilzomib and dexamethasone maintenance following salvage ASCT in multiple myeloma: a randomised phase 2 trial by the Nordic Myeloma Study Group","volume":"108","author":"Gregersen","year":"2022","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.heliyon.2024.e36311_bib18","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.3324\/haematol.2021.278399","article-title":"Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUKfive)","volume":"106","author":"Yong","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.heliyon.2024.e36311_bib19","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosi\u00f1ol","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e36311_bib20","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1038\/leu.2017.35","article-title":"Bortezomib and thalidomide maintenance after stem cell transplantation for multiple myeloma: a PETHEMA\/GEM trial","volume":"31","author":"Rosi\u00f1ol","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.heliyon.2024.e36311_bib21","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36311_bib22","first-page":"470","article-title":"The diagnosis and treatment of multiple myeloma","volume":"113","author":"Gerecke","year":"2016","journal-title":"Dtsch Arztebl Int"},{"key":"10.1016\/j.heliyon.2024.e36311_bib23","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.annonc.2020.11.014","article-title":"Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"32","author":"Dimopoulos","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.heliyon.2024.e36311_bib24","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/blood-2009-01-199604","article-title":"Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells","volume":"114","author":"Hideshima","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e36311_bib25","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.1182\/blood-2007-01-065888","article-title":"Potent activity of carfilzomib, a novel, irreversible inhibitor of the ubiquitin-proteasome pathway, against preclinical models of multiple myeloma","volume":"110","author":"Kuhn","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.heliyon.2024.e36311_bib26","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1080\/14656566.2017.1404575","article-title":"An overview of the role of carfilzomib in the treatment of multiple myeloma","volume":"18","author":"Ziogas","year":"2017","journal-title":"Expet Opin. Pharmacother."},{"key":"10.1016\/j.heliyon.2024.e36311_bib27","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/bcj.2017.31","article-title":"Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment","volume":"7","author":"Dimopoulos","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.heliyon.2024.e36311_bib28","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/cncr.32601","article-title":"Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database","volume":"126","author":"Fakhri","year":"2020","journal-title":"Cancer"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024123420?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024123420?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T23:03:08Z","timestamp":1773183788000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024123420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":28,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2405844024123420"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36311","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Meta-analysis of effectiveness and safety of proteasome inhibitor-dependent maintenance treatment for multiple myeloma a systematic review","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e36311","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e36311"}}